XSHE
002422
Market cap9.21bUSD
Oct 09, Last price
39.72CNY
1D
2.50%
1Q
-9.87%
Jan 2017
146.40%
IPO
11.26%
Name
Sichuan Kelun Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Key people
Gexin Liu
Chairman of the Board · since 2003
Degui Lai
Chief Financial Officer, Deputy General Manager · since 2014
Hao Feng
Deputy General Manager, Secretary of the Board · since 2014
Yihong Liao
Deputy General Manager · since 2022
Hongbo Tan
Deputy General Manager · since 2013
Juncai Wei
Deputy General Manager · since 2012
Zhonghua Wu
Deputy General Manager · since 2016
Junyou Ge
Director · since 2024
Director · since 2019
Sichuan Liu
General Manager, Director · since 2015
Xianxiang Zhou
Director · since 2024
Jinbo Gao
Independent Director · since 2021
Independent Director · since 2021
Fuqing Wang
Independent Director · since 2024
Headquarters & legal address
成都市新都卫星城工业开发区南二路
成都市, SC 100000
CN
成都市, SC 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||